Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer

• Status: Recruiting
• Trial end date: 2024-10-28
• Target enrollment: 0
• Participant gender: All

Summary

This trial will be a non-randomized, Phase I trial to evaluate safety, tolerability, biodistribution, radiation dosimetry, pharmacokinetics and PET imaging properties following an infusion of 37 MBq (1 mCi) of 89Zr-labeled hNd2* (NMK89) in patients with pancreatic cancer that are positive for MUC5AC. Image acquisition is conducted using a PET/CT machine.

• hNd2: Recombinant humanized Nd2 (anti-human MUC5AC monoclonal antibody)

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nihon Medi-Physics Co., Ltd.

Criteria

Inclusion Criteria:

1. Willing and able to provide informed consent.

2. Male or female ≥ 18 years of age.

3. Histologically confirmed diagnosis of pancreatic adenocarcinoma.

4. Willing to provide biopsy specimens for purposes of confirmation of MUC5AC expression.

5. Confirmed MUC5AC expression at pre-screening.

6. Measurable disease.

7. Female patients of child-bearing potential must have a negative serum pregnancy test within 30 days prior to infusion of NMK89.

8. Willing to comply with the study protocol requirements.

9. Willing to provide a tumor resection specimen or biopsy specimen, if the patient undergoes tumor resection or biopsy between Day 16 and Day 60.

Exclusion Criteria:

1. Known hypersensitivity to the investigational medicinal product (IMP) or any of the excipients.

2. History of another primary cancer within the 2 years prior to enrollment, except for the curatively treated in situ cancers.

3. Exposure to any investigational treatments within 30 days prior to the planned date of infusion of NMK89.

4. Ongoing toxicity ≥ Grade 2.

5. Pleural effusion or peritoneal fluid ≥ Grade 3.

6. Active hepatitis B, hepatitis C, HIV, or other progressing infectious disease.

7. Uncontrolled diabetes.

8. Autoimmune disease or idiopathic thrombocytopenic purpura.

9. Exposure to any radiopharmaceuticals.

10. Planned antineoplastic therapies on the planned date of NMK89 infusion.

11. Use of bevacizumab or any other anti-angiogenic agent.

12. Uncontrolled intercurrent illness.

13. ECOG PS: ≥ 2.

14. Participants do not have adequate organ and marrow function.

15. Female patients that are pregnant or breast-feeding.

16. Positive urine screen for illegal drugs, or abuse of prescribed drugs at Screening.

17. Participants with contraindications to contrast agent injection used for diagnostic CT.

18. Deemed inappropriate to participate by the investigator.